Center-Authored Papers

Filters: Author is Bekker, Linda-Gail  [Clear All Filters]
2008
Jaspan HB, Cunningham CK, Tucker TJP, Wright PF, Self SG, Sheets RL, Rogers AS, Bekker L-G, Wilson CM, Duerr A et al..  2008.  Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads.. Journal of acquired immune deficiency syndromes (1999). 47(1):86-92. Abstract
2011
Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, Gray G, Bekker L-G, McElrath MJ et al..  2011.  A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204).. PloS one. 6(8):e21225. Abstract
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker L-G, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH et al..  2011.  Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.. The Lancet infectious diseases. 11(7):507-15. Abstract
Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, Clark S, Ng'ang'a D, Brandariz KL, Abbink P et al..  2011.  International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.. Vaccine. 29(32):5203-9. Abstract
2012
Latka MH, Fielding K, Gray GE, Bekker L-G, Nchabeleng M, Mlisana K, Nielson T, Roux S, Mkhize B, Mathebula M et al..  2012.  Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women.. PloS one. 7(4):e31387. Abstract
2014
Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker L-G, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S et al..  2014.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.. The Lancet infectious diseases. 14(5):388-96. Abstract
Hopkins KL, Laher F, Otwombe K, Churchyard G, Bekker L-G, De Rosa S, Nchabeleng M, Mlisana K, Kublin J, Gray G.  2014.  Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses.. PloS one. 9(8):e103446. Abstract
Volk JE, Hessol NA, Gray GE, Kublin JG, Churchyard GJ, Mlisana K, Nchabeleng M, Buchbinder SP, Bekker L-G.  2014.  The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants.. International journal of STD & AIDS. 25(5):332-40. Abstract
Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker L-G, Self SG.  2014.  Tuberculosis vaccines and prevention of infection.. Microbiology and molecular biology reviews : MMBR. 78(4):650-71. Abstract
2015
Palanee-Phillips T, Schwartz K, Brown ER, Govender V, Mgodi N, Kiweewa FM, Nair G, Mhlanga F, Siva S, Bekker L-G et al..  2015.  Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.. PloS one. 10(6):e0128857. Abstract
Moodie Z, Metch B, Bekker L-G, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C et al..  2015.  Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.. PloS one. 10(9):e0137666. Abstract
2016
Churchyard G, Mlisana K, Karuna S, Williamson A-L, Williamson C, Morris L, Tomaras GD, De Rosa SC, Gilbert PB, Gu N et al..  2016.  Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.. PloS one. 11(9):e0161753. Abstract
Cranston RD, Lama JR, Richardson BA, Carballo-Diéguez A, Kunjara Na Ayudhya RP, Liu K, Patterson KB, Leu C-S, Galaska B, Jacobson CE et al..  2016.  MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Abstract
Baden LR, Karita E, Mutua G, Bekker L-G, Gray G, Page-Shipp L, Walsh SR, Nyombayire J, Anzala O, Roux S et al..  2016.  Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.. Annals of internal medicine. Abstract
Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Kiweewa FM, Nair G, Mhlanga F et al..  2016.  Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.. The New England journal of medicine. Abstract
Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR et al..  2016.  Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.. PLoS pathogens. 12(7):e1005742. Abstract
Gray GE, Mayer KH, Elizaga ML, Bekker L-G, Allen M, Morris L, Montefiori D, De Rosa SC, Sato A, Gu N et al..  2016.  Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap.. Clinical and vaccine immunology : CVI. 23(6):496-506. Abstract
2017
Carballo-Diéguez A, Balán IC, Brown W, Giguere R, Dolezal C, Leu C-S, Marzinke MA, Hendrix CW, Piper JM, Richardson BA et al..  2017.  High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.. PloS one. 12(7):e0181607. Abstract
Karim SAS, Abdool Karim Q, Abimiku A'le, Bekker L-G, Bukusi EA, Deschamps MMH, Derbew M, Garcia PJ, Gray G, Kamya MR et al..  2017.  Closing the NIH Fogarty Center threatens US and global health.. Lancet (London, England). 390(10093):451.